Ciphergen Names Chief Scientific Officer
June 19 2006 - 10:00AM
PR Newswire (US)
FREMONT, Calif., June 19 /PRNewswire-FirstCall/ -- Ciphergen
Biosystems, Inc. (NASDAQ:CIPH) announced today that Eric T. Fung,
M.D., Ph.D. has been promoted to the position of Chief Scientific
Officer. In his new position, Dr. Fung will be responsible for
setting the strategic direction of Ciphergen's clinical development
programs, integrating these programs with the Company's research
and development efforts, and helping drive growth strategies in the
emerging area of predictive diagnostics. In addition, Dr. Fung will
chair the newly formed Scientific Advisory Board. "Eric has played
a key role in developing and managing our diagnostic biomarker
pipeline and fostering our collaborations with key accounts such as
the Johns Hopkins Medical School, the MD Anderson Cancer Center,
and University College London," stated Gail S. Page, President and
CEO. "His combination of clinical and scientific experience will
help guide us towards commercialization of high value diagnostic
tests." Dr. Fung joined Ciphergen in 2000 as a lead scientist in
the newly formed Biomarker Discovery Center(R) laboratories and
managed many of Ciphergen's academic and pharmaceutical
collaborations. He was most recently Vice President of Clinical and
Medical Affairs. Prior to joining Ciphergen, Dr. Fung was a Howard
Hughes sponsored researcher at Stanford University. Dr. Fung
completed his anatomic pathology internship at Stanford Medical
School, and obtained his M.D. and Ph.D. degree in molecular
neuroscience from the Johns Hopkins University School of Medicine.
He graduated with a BS in biology with honors from the California
Institute of Technology. Dr. Fung also currently holds an Adjunct
Assistant Professor position in the Department of Pathology at the
Johns Hopkins University School of Medicine. Dr. Fung is an author
on over 75 publications and abstracts. About Ciphergen Ciphergen is
dedicated to translating protein biomarkers and panels of
biomarkers into protein molecular diagnostic tests that improve
patient care. We are also focused on providing collaborative
R&D services through our Biomarker Discovery Center(R)
laboratories for biomarker discovery for new diagnostic tests as
well as pharmacoproteomic services for improved drug toxicology,
efficacy and theranostic assays. Ciphergen develops, manufactures
and markets a family of ProteinChip(R) Systems and services for
clinical, research and process proteomics applications. ProteinChip
Systems enable protein discovery, validation, identification and
assay development to provide researchers with predictive,
multi-marker assay capabilities and a better understanding of
biological function at the protein level. Additional information
about Ciphergen can be found at http://www.ciphergen.com/. Safe
Harbor Statement Note Regarding Forward-Looking Statements: This
press release contains forward-looking statements. For purposes of
the Private Securities Litigation Reform Act of 1995 (the "Act"),
Ciphergen disclaims any intent or obligation to update these
forward-looking statements, and claims the protection of the Safe
Harbor for forward-looking statements contained in the Act.
Examples of such forward-looking statements include statements
regarding Ciphergen's ability to create and commercialize
diagnostic tests that are useful in the prevention of disease.
Actual results may differ materially from those projected in such
forward-looking statements due to various factors, including the
risk that Ciphergen may not be able to develop diagnostic tests
based on the discoveries of certain biomarkers. Investors should
consult Ciphergen's filings with the Securities and Exchange
Commission, including its Form 10-K filed March 17, 2006, for
further information regarding these and other risks related to the
Company's business. Ciphergen, ProteinChip and Biomarker Discovery
Center are registered trademarks of Ciphergen Biosystems, Inc.
DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers,
Investor Relations for Ciphergen Biosystems, Inc., +1-510-505-2297
Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From May 2024 to Jun 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2023 to Jun 2024